S.Korea's SK Bioscience in deal with AstraZeneca on vaccine

SEOUL, July 21 (Reuters) - SK Bioscience 285130.KS has signed a letter of intent with Britain's AstraZeneca AZN.L for global production of its experimental COVID-19 vaccine, the South Korean company said on Tuesday.

South Korea's health ministry will also participate in the cooperation, the company said in a statement.

(Reporting by Sangmi Cha; editing by Jason Neely)

((; +82 2 3704 5646; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.